var data={"title":"Busulfan: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Busulfan: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5772?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=busulfan-drug-information\" class=\"drug drug_general\">see &quot;Busulfan: Drug information&quot;</a> and <a href=\"topic.htm?path=busulfan-patient-drug-information\" class=\"drug drug_patient\">see &quot;Busulfan: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708634\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Busulfan is a potent drug. Busulfan oral tablets should not be used unless a diagnosis of chronic myelogenous leukemia (CML) has been adequately established and the responsible health care provider is knowledgeable in assessing response to chemotherapy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Bone marrow suppression:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Busulfan tablets can induce severe bone marrow hypoplasia. Reduce or discontinue the dosage of oral busulfan immediately at the first sign of any unusual depression of bone marrow function as reflected by an abnormal decrease in any of the formed elements of the blood. A bone marrow examination should be performed if the bone marrow status is uncertain.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Busulfan injection causes severe and prolonged myelosuppression at the recommended dosage. Hematopoietic progenitor cell transplantation is required to prevent potentially fatal complications of the prolonged myelosuppression.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143389\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Busulfex;</li>\n      <li>Myleran</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143390\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Busulfex;</li>\n      <li>Myleran</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045642\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Alkylating Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045635\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=busulfan-drug-information\" class=\"drug drug_general\">see &quot;Busulfan: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Dose, frequency, number of doses, and/or start date may vary by protocol and treatment phase. Refer to individual protocols and/or therapeutic drug monitoring. <b>Note:</b> Premedicate with prophylactic anticonvulsant therapy (eg, phenytoin, levetiracetam, benzodiazepines, or valproic acid) beginning 12 hours prior to high-dose busulfan treatment and continuing for 24 hours after last busulfan dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Dosing presented as mg/kg and mg/m<sup>2</sup>; use extra precaution. Busulfan is associated with a moderate emetic potential (depending on dose and/or administration route); antiemetics are recommended to prevent nausea and vomiting (Dupuis 2011). Antiemetics are recommended when used for transplantation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hematopoietic stem cell transplant (HSCT) conditioning regimen:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Infants, Children, and Adolescents: <b>Note:</b> Dosing based on actual body weight, including obese individuals (Bubalo 2014):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Initial: </i>Therapeutic drug monitoring should be considered early in regimen (eg, after first dose) and doses adjusted accordingly.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&le;12 kg: IV: 1.1 mg/kg/dose every 6 hours for 16 doses (over 4 days followed by cyclophosphamide)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;12 kg: IV: 0.8 mg/kg/dose every 6 hours for 16 doses (over 4 days followed by cyclophosphamide)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Dosing adjustment:</i> Doses adjusted based upon AUC or steady state concentration (CSS) depending upon protocol. The desired AUCs or CSSs are variable and may be dependent upon multiple factors, including indication for transplant, type of transplant, and donor source; specific protocols should be consulted. A desired AUC of 900 to 1,350 micromolar/minute has been suggested per the manufacturer, and CSS of 600 to 900 ng/mL &plusmn; 10% has also been reported (Bolinger 2013; Horn 2006; Law 2012). Adjusted dose may be determined from the following formulas:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Adjusted dose (mg) = Actual dose (mg) x [target AUC (micromolar&bull;minute) / actual AUC (micromolar&bull;minute)]</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Adjusted dose (mg) = Actual dose (mg) x [target CSS (ng/mL) / actual CSS (ng/mL)]</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Reduced intensity conditioning regimens: </i>Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">12-dose regimen: Children &ge;2 and Adolescents: IV: 0.8 mg/kg/dose every 6 hours for 12 doses starting on Day -6; used in combination with fludarabine and melphalan for patients receiving haploidentical, peripheral blood HSCT for acute leukemia (Jaiswal 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">8-dose regimen: Infants, Children, and Adolescents: 0.8 mg/kg/dose for one dose on either day -7 (related donor) or day -10 (unrelated donor or cord recipient) prior to transplant, followed by 7 additional doses of ~0.8 mg/kg/dose every 6 hours (actual dose based on pharmacokinetic analysis after initial dose) beginning days -3 and -2 (related donor) or days -6 and -5 (unrelated donor or cord recipient) prior to transplant; used in combination with fludarabine and antithymocyte globulin (rabbit). In clinical trials, there was no minimum age for inclusion; the youngest patient treated was 2 years (Pulsipher 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Once-Daily Dosing: Limited data available: <b>Note:</b> Dosing based on actual body weight up to 120% of IBW, then dose based on adjusted dosing weight (ideal body weight plus 50% of the difference between ideal and actual weight) based on experience from adult patients (De Lima 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Infants &lt;1 year: IV: 80 mg/<b>m<sup>2</sup></b>/dose over 3 hours once daily for 4 days prior to HSCT, starting on Day -8 (combined with cyclophosphamide or fludarabine and etoposide); dose adjustment (Days -7 to -5) to target AUC 4,384 to 4,628 micromolar&bull;minute/liter/day has been reported (Lee 2012; Lee 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Children &ge;1 year and Adolescents: IV: 120 mg/<b>m<sup>2</sup></b>/dose over 3 hours once daily for 4 days prior to HSCT, starting on Day -8 (combined with cyclophosphamide or fludarabine and etoposide); dose adjustment (Days -7 to -5) to target AUC 4,384 to 4,628 micromolar&bull;minute/liter/day has been reported (Lee 2012; Lee 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: <b>Note:</b> Dosing based on actual body weight, including obese individuals (Bubalo 2014): <b>Note:</b> Not routinely used for HSCT conditioning regimens, IV formulation is the preferred dosage form. Dosing variable dependent upon indication for HSCT.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Acute Myeloid Leukemia</i>: Limited data available: Adolescents &ge;16 years: Oral: 1 mg/kg/dose every 6 hours for 16 doses on days -9 to -6 in combination with cyclophosphamide (Cassileth 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Thalassemia major</i>: Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Class 1 or Class 2 (ie, low-risk for GVHD or transplant mortality):</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Infants and Children &lt;3 years: Oral: 1.25 mg/kg every 6 hours for 16 doses on day -9 to day -6 prior to transplant in combination with cyclophosphamide and antithymocyte globulin (horse) (Hussein 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Children &ge;3 years and Adolescents: Oral: 1 mg/kg/dose every 6 hours for 16 doses prior to transplant; on days -9 to -6 in combination with cyclophosphamide and antithymocyte globulin (horse) (Hussein 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Class 3 (ie, high-risk disease): Children &ge;10 years and Adolescents: Oral: 2 mg/kg/dose every 12 hours for 4 doses on days -8 and -7 in combination with fludarabine and antithymocyte globulin (horse) (Hussein 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chronic myelogenous leukemia (CML), palliation:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Remission induction: 0.06 mg/kg/dose once daily or 1.8 mg/m<sup>2</sup>/dose once daily; usual range: 4 to 8 mg/day; titrate dose (or withhold) to maintain leukocyte counts &ge;15,000/mm<sup>3</sup>; doses &gt;4 mg/day should be reserved for patients with the most compelling symptoms</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance: When leukocyte count &ge;50,000/mm<sup>3</sup>: Resume induction dose <b>or</b> (if remission &lt;3 months) 1 to 3 mg/day (to control hematologic status and prevent relapse)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hematopoietic stem cell (HSCT) conditioning regimen:</b> IV: 0.8 mg/kg/dose every 6 hours for 4 days (a total of 16 doses) beginning 7 days prior to transplant (followed by cyclophosphamide); <b>Note:</b> Use ideal body weight or actual body weight, (whichever is lower) for dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Obesity: For obese or severely obese patients, use of an adjusted body weight [IBW + 0.25 x (actual - IBW)] is recommended (by the manufacturer)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: There are no dosage adjustments provided in the manufacturer's labeling; elimination appears to be independent of renal function; some clinicians suggest adjustment is not necessary (Aronoff 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143366\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Busulfex: 6 mg/mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 6 mg/mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 6 mg/mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Myleran: 2 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143351\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045646\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Busulfan is associated with a moderate emetic potential (depending on dose and/or administration route); antiemetics may be recommended to prevent nausea and vomiting (Dupuis 2011). Antiemetics are recommended when used for transplantation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: May be administered without regard to meals. To facilitate ingestion of high doses (for HSCT), may insert multiple tablets into clear gelatin capsules for administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Infuse over 2 hours through a central venous catheter; use an administration set with a minimal residual priming volume (2 to 5 mL for adults and 1 to 3 mL for pediatric patients); flush line before and after each infusion with 5 mL of D5W or NS. Do <b>not</b> use polycarbonate syringes or filter needles for preparation or administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130910\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration. For IV preparation, NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and (if compatible) closed system transfer devices (CSTDs). Double gloving, a gown, and (if compatible and dosage form allows) CSTDs are required during IV administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143384\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Store intact vials under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Solutions diluted in sodium chloride (NS) injection or dextrose 5% in water (D<sub>5</sub>W) for infusion are stable for up to 8 hours at room temperature (25&deg;C [77&deg;F]); the infusion must also be completed within that 8-hour timeframe. Dilution of busulfan injection in NS is stable for up to 12 hours refrigerated (2&deg;C to 8&deg;C); the infusion must be completed within that 12-hour timeframe.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet: Store at  25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045645\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Palliative treatment of chronic myelogenous leukemia (CML) [FDA approved in pediatric patients (age not specified) and adults]; has also been used as a conditioning regimen prior to hematopoietic stem cell transplant. <b>Note:</b> Although an FDA-labeled indication, the use of busulfan for palliative treatment of chronic myelogenous leukemia in pediatric patients is no longer considered a treatment option by experts.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for CML in combination with cyclophosphamide (FDA approved in pediatric patients [age not specified] and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143443\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Myleran may be confused with Alkeran, Leukeran, melphalan, Mylicon</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">A solvent in IV busulfan, N, N-dimethylacetamide, is incompatible with many closed system transfer devices (CSTDs) used for preparing injectable antineoplastics. The plastic components of CSTDs may dissolve and result in subsequent leakage and potential infusion of dissolved plastic into the patient (ISMP [Smetzer 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143440\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intravenous: </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Atrial fibrillation, cardiac arrhythmia, cardiac tamponade (children with thalassemia), cardiomegaly, catheter site thrombosis (central venous catheter), chest pain, complete atrioventricular block, ECG abnormality, edema, flushing, hypertension, hypotension, left heart failure, pericardial effusion, tachycardia, thrombosis, vasodilatation, ventricular premature contractions</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Agitation, anxiety, brain disease, cerebral hemorrhage, chills, coma, confusion, delirium, depression, dizziness, drowsiness, hallucination, headache, insomnia, lethargy, pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acne vulgaris, alopecia, erythema nodosum, exfoliative dermatitis, maculopapular rash, pruritus, skin discoloration, skin rash, vesicular eruption, vesiculobullous dermatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hot flash, hyperglycemia, hypervolemia, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia, weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, constipation, dyspepsia, esophagitis, diarrhea, gastrointestinal fullness, hematemesis, hiccups, intestinal obstruction, mucositis, nausea (more common in adults), pancreatitis, rectal disease, rectal pain, stomatitis (more common in adults), vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Dysuria, hematuria, hemorrhagic cystitis, oliguria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, bone marrow depression, lymphocytopenia (children), neutropenia (onset: 4 days; median recovery: 13 days [with G-CSF support]), prolonged prothrombin time, thrombocytopenia (median onset: 5 to 6 days)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatic sinusoidal obstruction syndrome (formerly known as hepatic veno-occlusive disease; more common in children), hepatomegaly, hyperbilirubinemia, increased serum alkaline phosphatase, increased serum ALT, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Graft versus host disease (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Inflammation at injection site, pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, myalgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Ear disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased blood urea nitrogen, increased serum creatinine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Asthma, atelectasis, cough, dyspnea, epistaxis, hemoptysis, hyperventilation, hypoxia, pharyngitis, pleural effusion, pneumonia (children), pulmonary alveolar hemorrhage, pulmonary disease, pulmonary interstitial fibrosis, rhinitis, sinusitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Oral:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Seizure (despite prophylactic seizure therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin hyperpigmentation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Amenorrhea, ovarian failure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Bone marrow depression (including anemia, leukopenia, thrombocytopenia), pancytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pulmonary interstitial fibrosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b> IV and/or Oral:</b> Rare but important or life-threatening: Acute leukemia, adrenocortical insufficiency, alopecia (permanent), aplastic anemia (may be irreversible), azoospermia, capillary leak syndrome, cardiomyopathy (endocardial fibrosis), cataract (rare), cheilosis, cholestatic jaundice, corneal thinning, erythema multiforme, esophageal varices (with continuous busulfan and thioguanine therapy), febrile neutropenia, fragile skin, gynecomastia, hepatic fibrosis (centrilobular sinus), hepatic necrosis, hepatic sinusoidal obstruction syndrome (formerly known as hepatic veno-occlusive disease) (oral), lens disease (including particulate matter deposition), malignant neoplasm, myasthenia gravis, porphyria cutanea tarda, pulmonary fibrosis (with bronchopulmonary dysplasia), recall skin sensitization (skin rash), sepsis, sterility, testicular atrophy, thrombotic thrombocytopenic purpura, tumor lysis syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143373\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to busulfan or any component of the formulation; oral busulfan is contraindicated in patients without a definitive diagnosis of chronic myeloid leukemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Oral busulfan: Neutropenia or thrombocytopenia; disease that has demonstrated resistance to busulfan</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143355\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: <b>[US Boxed Warning]: Severe and prolonged bone marrow suppression commonly occurs; reduce dose or discontinue oral busulfan for unusual suppression; may require bone marrow biopsy. Hematopoietic progenitor cell transplantation is required to prevent potentially fatal complications from prolonged myelosuppression due to IV busulfan.</b> May result in severe neutropenia, thrombocytopenia, anemia, bone marrow failure, and/or severe pancytopenia; pancytopenia may be prolonged (1 month up to 2 years) and may be reversible. When used for transplantation, monitor CBC with differential daily during treatment and until engraftment. The onset of neutropenia is a median of 4 days post-transplant; recovery is within a median of 13 days following allogeneic transplant (with prophylactic G-CSF use in most patients). Thrombocytopenia occurred at a median of 5 to 6 days. Use with caution in patients with compromised bone marrow reserve (due to prior treatment or radiation therapy). Monitor closely for signs of infection (due to neutropenia) or bleeding (due to thrombocytopenia). May require antibiotic therapy and platelet and red blood cell support.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular: Cardiac tamponade has been reported in children with thalassemia treated with high dose oral busulfan in combination with cyclophosphamide. Abdominal pain and vomiting preceded tamponade in most children. Monitor for signs/symptoms and evaluate/treat promptly if cardiac tamponade is suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: Busulfan is associated with a moderate emetic potential (depending on dose and/or administration route); antiemetics may be recommended to prevent nausea and vomiting (Dupuis 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic sinusoidal obstruction syndrome: High busulfan area under the concentration versus time curve (AUC) values (&gt;1500 micromolar&bull;minute) are associated with increased risk of hepatic sinusoidal obstruction syndrome (SOS; formerly called veno-occlusive disease [VOD]) due to conditioning for allogenic HSCT. Patients with a history of radiation therapy, prior chemotherapy (&ge;3 cycles), or prior stem cell transplantation are also at increased risk of hepatic SOS at recommended doses regimens. Oral busulfan doses above 16 mg/kg (based on IBW) and concurrent use with alkylating agents may also increase the risk for hepatic SOS. Monitor liver function tests (serum transaminases, alkaline phosphatase, and bilirubin) daily until 28 days post-transplant to detect hepatotoxicity (which may preclude hepatic SOS).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary toxicity: Bronchopulmonary dysplasia with pulmonary fibrosis (&ldquo;busulfan lung&rdquo;) is associated with chronic busulfan use; onset is delayed with symptoms occurring at an average of 4 years (range: 4 months to 10 years) after treatment; may be fatal. Symptoms generally include a slow onset of cough, dyspnea and fever (low-grade), although acute symptomatic onset may also occur. Diminished diffusion capacity and decreased pulmonary compliance have been noted with pulmonary function testing. Differential diagnosis should rule out opportunistic pulmonary infection or leukemic pulmonary infiltrates; may require lung biopsy. Discontinue busulfan if toxicity develops. Pulmonary toxicity may be additive if administered with other cytotoxic agents also associated with pulmonary toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Secondary malignancies: Tumors and acute leukemias have been reported following use. Chromosomal alterations may also occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Seizures have been reported with IV busulfan and with high-dose oral busulfan. When using as a conditioning regimen for transplant, initiate prophylactic anticonvulsant therapy (eg, phenytoin, levetiracetam, benzodiazepines, or valproic acid) prior to treatment. Use with caution in patients predisposed to seizures, with a history of seizures, head trauma, or with other medications associated with inducing seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tissue dysplasia: Cellular dysplasia in many organs has been observed (in addition to lung dysplasia); giant hyperchromatic nuclei have been noted in adrenal glands, liver, lymph nodes, pancreas, thyroid, and bone marrow. May obscure routine diagnostic cytologic exams (eg, cervical smear).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticonvulsants: Phenytoin increases busulfan clearance by &ge;15%; busulfan kinetics and dosing recommendations for high-dose HSCT conditioning were studied with concomitant phenytoin. If alternate anticonvulsants are used, busulfan clearance may be decreased and dosing should be monitored accordingly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dimethylacetamide: The solvent in IV busulfan, dimethylacetamide (DMA) may be associated with hepatotoxicity, hallucinations, somnolence, lethargy, and confusion. N,N-dimethylacetamide is incompatible with many closed-system transfer devices (CSTDs) used for preparing injectable antineoplastics (ISMP [Smetzer 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: <b>[US Boxed Warning]: According to the manufacturer, oral busulfan should not be used until CML diagnosis has been established. The responsible health care provider should be experienced in assessing response to chemotherapy.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143428\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143360\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13103&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acetaminophen: May increase the serum concentration of Busulfan.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antifungal Agents (Azole Derivatives, Systemic): May increase the serum concentration of Busulfan. Isavuconazonium considerations are addressed in separate monographs.<b> Exceptions: </b>Isavuconazonium Sulfate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blinatumomab: May increase the serum concentration of Busulfan.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May increase the serum concentration of Busulfan.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of Busulfan.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ifosfamide: Busulfan may enhance the adverse/toxic effect of Ifosfamide. Specifically, the risk of hemorrhagic cystitis may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetroNIDAZOLE (Systemic): May increase the serum concentration of Busulfan. Management: The toxic effects of busulfan may be greatly increased with concomitant use of metronidazole. This combination should probably be avoided when possible.  If these agents must be used together, increased monitoring for busulfan toxicity is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of Busulfan.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propacetamol: May increase the serum concentration of Busulfan.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143362\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3880598\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events were observed in animal reproduction studies. May cause fetal harm if administered during pregnancy. The solvent in IV busulfan, DMA, is also associated with teratogenic effects in animal studies.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Females of childbearing potential should use effective contraception to avoid pregnancy during treatment and for 6 months after completion of therapy. Males with female partners of reproductive potential should use effective contraception during treatment and for 3 months after completion of therapy.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Busulfan may impair fertility in females and males.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045641\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelet count (weekly for palliative treatment in adults; daily until engraftment for HSCT); liver function tests, bilirubin, and alkaline phosphatase daily through 28 days post transplant.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">If conducting therapeutic drug monitoring for AUC calculations in HSCT, monitor busulfan plasma concentrations at appropriate collection times (record collection times); for IV infusion; collect blood sample from a different port than that used for infusion. Blood samples should be placed on wet ice immediately after collection and should be centrifuged (at 4&deg;C [39.2&deg;F]) within 1 hour. The plasma, harvested into appropriate cryovial storage tubes, should be frozen immediately at -20&deg;C (-4&deg;F). All plasma samples should be sent frozen (on dry ice) to the assay laboratory for the determination of plasma busulfan concentrations. Specific collection times may vary, consult specific protocols; for calculating AUC, the manufacturer suggests the following:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">From the end of the infusion of the first dose, collect at 2 hours, 4 hours, and 6 hours (immediately prior to the next dose).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Any other dose, collect a pre-infusion concentration, then at 2 hours (end of infusion), 4 hours, and 6 hours (immediately prior to the next dose).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143354\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Busulfan is an alkylating agent which reacts with the N-7 position of guanosine and interferes with DNA replication and transcription of RNA. Busulfan has a more marked effect on myeloid cells than on lymphoid cells and is also very toxic to hematopoietic stem cells. Busulfan exhibits little immunosuppressive activity. It interferes with the normal function of DNA by alkylation and cross-linking the strands of DNA.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143372\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid and complete </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: Pediatric (IV): ~0.64 L/kg; crosses blood brain barrier and distributes into CSF with levels equal  to plasma </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~32% to plasma proteins and 47% to red blood cells</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensively hepatic (may increase with multiple doses); glutathione conjugation followed by oxidation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: Children &ge;13 years and adults: 80% (range: 47% to 103%); Children 1.5 to 6 years: 68% (range: 22% to 120%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 2 to 3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral: ~1 hour; IV: Within 5 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (25% to 60% predominantly as metabolites; &lt;2% as unchanged drug)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance:  Children: 3.37 mL/minute/kg; Adults: 2.52 mL/minute/kg (range: 1.49 to 4.31 mL/minute/kg) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10893684\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;\">A 2 mg/mL oral suspension can be prepared in a vertical flow hood with tablets and simple syrup. Crush one-hundred-twenty 2 mg tablets in a mortar and reduce to a fine powder. Add small portions of simple syrup and mix to a uniform paste; mix while adding the simple syrup in incremental proportions to <b>almost</b> 120 mL; transfer to a graduated cylinder, rinse mortar and pestle with simple syrup, and add quantity of vehicle sufficient to make 120 mL. Transfer contents of the graduated cylinder into an amber prescription bottle. Label &ldquo;shake well&rdquo;, &ldquo;refrigerate&rdquo;, and &ldquo;caution chemotherapy&rdquo;. Stable for 30 days.</p>\n    <div class=\"reference\">Allen LV, &quot;Busulfan Oral Suspension,&quot; <i>US Pharm</i>, 1990, 15:94-5. </div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143375\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Busulfan Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg/mL (10 mL): $1,216.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Busulfex Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg/mL (10 mL): $2,763.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Myleran Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (25): $702.70</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143376\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Busilvex (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, HR, IE, IT, LB, MT, MX, NL, NO, PL, PT, RO, RU, SE, SK, TR, UA);</li>\n      <li>Busulf (PK);</li>\n      <li>Busulfex (AU, CN, HK, IL, JP, KR, MY, SG, TH, TW, VN);</li>\n      <li>Myleran (AE, AR, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CR, CY, CZ, DE, DO, EC, EE, EG, ET, FR, GB, GH, GM, GN, GR, GT, GY, HK, HN, HR, IE, IL, IN, IQ, IR, IS, IT, JM, JO, KE, KW, LB, LK, LR, LT, LU, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NZ, OM, PA, PE, PL, PT, QA, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SR, SV, SY, TH, TN, TR, TT, TW, TZ, UA, UG, UY, YE, ZA, ZM, ZW);</li>\n      <li>Myleran-2 (CU);</li>\n      <li>Myran (SG)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bolinger AM, Zangwill AB, Slattery JT, et al. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation.<i> Bone Marrow Transplan</i>t. 2001;28(11):1013-1018.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/busulfan-pediatric-drug-information/abstract-text/11781609/pubmed\" target=\"_blank\" id=\"11781609\">11781609</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bubalo J, Carpenter PA, Majhail N, et al. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. <i>Biol Blood Marrow Transplant</i>. 2014;20(5):600-616.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/busulfan-pediatric-drug-information/abstract-text/24462742 /pubmed\" target=\"_blank\" id=\"24462742 \">24462742 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Busufex (busulfan) (prescribing information). Rockville, MD: Otsuka America Pharmaceutical, Inc; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. <i>NEJM</i>. 1998;339(23):1649-1656.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/busulfan-pediatric-drug-information/abstract-text/9834301/pubmed\" target=\"_blank\" id=\"9834301\">9834301</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Lima M, Couriel D, Thall PF, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. <i>Blood</i>. 2004;104(3):857-864.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/busulfan-pediatric-drug-information/abstract-text/15073038/pubmed\" target=\"_blank\" id=\"15073038\">15073038</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Drabco K, Raciborska A, Bilska K, et al. Consolidation of first-line therapy with busulphan and melphalan, and autologous stem cell rescue in children with Ewing&rsquo;s sarcoma. <i>Bone Marrow Transplantation</i>. 2012;47:1530-1534.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/busulfan-pediatric-drug-information/abstract-text/22609883/pubmed\" target=\"_blank\" id=\"22609883\">22609883</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Holdsworth M, et al. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patient. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/busulfan-pediatric-drug-information/abstract-text/23512831 /pubmed\" target=\"_blank\" id=\"23512831 \">23512831 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/busulfan-pediatric-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Horn B, Baxter-Lowe LA, Englert L, et al. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. <i>Bone Marrow Transplant</i>. 2006;37(3):263-269.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/busulfan-pediatric-drug-information/abstract-text/16327813/pubmed\" target=\"_blank\" id=\"16327813\">16327813</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ho VT, Aldridge J, Kim HT, et al, Comparison of tacrolimus and sirolimus (Tac/Sir) versus tacrolimus, sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.<i> Biol Blood Marrow Transplant</i>, 2009;15(7):844-850.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/busulfan-pediatric-drug-information/abstract-text/19539216/pubmed\" target=\"_blank\" id=\"19539216\">19539216</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hussein AA, Al-Zaben A, Ghatasheh L, et al. Risk adopted allogeneic hematopoietic stem cell transplantation using a reduced intensity regimen for children with thalassemia major. <i>Pediatr Blood Cancer</i>. 2013;60:1345-1349.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/busulfan-pediatric-drug-information/abstract-text/23424175/pubmed\" target=\"_blank\" id=\"23424175\">23424175</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practices. Acute Care Medication Safety Alert. 2015;20(4):2-3.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jaiswal SR, Chakrabarti A, Chatterjee S, et al. Haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide in children with advanced acute leukemia with fludarabine-, busulfan-, and melphalan-based conditioning. <i>Biol Blood Marrow Transplant</i>. 2016;22(3):499-504.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/busulfan-pediatric-drug-information/abstract-text/26612281/pubmed\" target=\"_blank\" id=\"26612281\">26612281</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Law J, Cowan MJ, Dvorak CC, et al. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution. <i>Biol Blood Marrow Transplant</i>. 2012;18(11):1656-1663.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/busulfan-pediatric-drug-information/abstract-text/22609040/pubmed\" target=\"_blank\" id=\"22609040\">22609040</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee JW, Kang HJ, Kim S, et al. Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients. <i>Biol Blood Marrow Transplant</i>. 2015;21(1):190-195.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/busulfan-pediatric-drug-information/abstract-text/25255163/pubmed\" target=\"_blank\" id=\"25255163\">25255163</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee JW, Kang HJ, Lee SH, et al. Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. Biol Blood Marrow Transplant. 2012 Jun;18(6):944-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/busulfan-pediatric-drug-information/abstract-text/22155501/pubmed\" target=\"_blank\" id=\"22155501\">22155501</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Le Gall JB, Milone MC, Waxman IM, et al. The pharmacokinetics and safety of twice daily I.V. BU during conditioning in pediatric allo-SCT recipients. <i>Bone Marrow Transplantation</i>. 2013;48:19-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/busulfan-pediatric-drug-information/abstract-text/22684047/pubmed\" target=\"_blank\" id=\"22684047\">22684047</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu H, Zhai X, Song Z, et al. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study. <i> J Hematol Oncol</i>. 2013;6:15-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/busulfan-pediatric-drug-information/abstract-text/23394705/pubmed\" target=\"_blank\" id=\"23394705\">23394705</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Myleran (busulfan) [prescribing information]. Mason, OH: Prasco Laboratories; November 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ozkaynak MF, Weinberg K, Kohn D, et al, &ldquo;Hepatic Veno-Occlusive Disease Post-Bone Marrow Transplantation in Children Conditioned With Busulfan and Cyclophosphamide: Incidence, Risk Factors, and Clinical Outcome,&rdquo; <i>Bone Marrow Transplant</i>, 1991, 7(6):467-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/busulfan-pediatric-drug-information/abstract-text/ 1908340 /pubmed\" target=\"_blank\" id=\" 1908340 \"> 1908340 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pulsipher MA, Boucher KM, Wall D, et al. Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313. <i>Blood</i>. 2009;114:1429-1436.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/busulfan-pediatric-drug-information/abstract-text/19528536/pubmed\" target=\"_blank\" id=\"19528536\">19528536</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Regazzi MB, Locatelli F, Buggia I, et al. Disposition of High Dose Busulfan in Pediatric Patients Undergoing Bone Marrow Transplantation,&rdquo; <i>Clin Pharmacol Ther</i>, 1993, 54(1):45-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/busulfan-pediatric-drug-information/abstract-text/8330465/pubmed\" target=\"_blank\" id=\"8330465\">8330465</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vassal G, Gouyette A, Hartmann O, et al, &ldquo;Pharmacokinetics of High-Dose Busulfan in Children,&rdquo; <i>Cancer Chemother Pharmacol</i>, 1989, 24(6):386-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/busulfan-pediatric-drug-information/abstract-text/2791192/pubmed\" target=\"_blank\" id=\"2791192\">2791192</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13103 Version 152.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708634\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F143389\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F143390\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1045642\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1045635\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F143366\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F143351\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1045646\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130910\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F143384\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1045645\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F143443\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F143440\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F143373\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F143355\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F143428\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F143360\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F143362\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3880598\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1045641\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F143354\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F143372\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F10893684\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F143375\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F143376\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13103|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=busulfan-drug-information\" class=\"drug drug_general\">Busulfan: Drug information</a></li><li><a href=\"topic.htm?path=busulfan-patient-drug-information\" class=\"drug drug_patient\">Busulfan: Patient drug information</a></li></ul></div></div>","javascript":null}